Chardan analyst Geulah Livshits lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $8 from $9 and keeps a Buy rating on the shares after the company announced data from the RIDGE-1 trial of TN-401 in PKP2-ACM. With this readout, Tenaya remains “very much in the competitive mix” for PKP2-ACM along with peers Lexeo Therapeutics (LXEO) and Rocket Pharmaceuticals (RCKT), both of which will also be providing updates on their respective programs over 2026, says the analyst, who updated the firm’s model to reflect dilution from Tenaya’s announced stock offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics 50M share Spot Secondary priced at $1.20
- FDA Lifts Hold on Tenaya’s MyPEAK-1 Trial
- Tenaya Therapeutics files to sell common stock, no amount given
- Tenaya Therapeutics announces interim data from cohort one of RIDGE-1 trial
- Tenaya Therapeutics announces clinical hold on MyPEAK-1 trial lifted by FDA